FDA approvals drop 8% in 2025, with fewer blockbusters; Brinsupri, Rhapsido make it to first-in-class list

Data Compilation
#PharmaFlow

Pipeline Prospector February 2026 highlights: Gilead buys Arcellx for US$ 7.8 bn; FDA okays Vanda’s psychotic pill

Stock Recap
#PipelineProspector

Octreotide Acetate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

60 API Suppliers, 27 USDMF, 9 CEP/COS, 4 JDMF, 8 EU WC, 1 KDMF, 20 NDC API, 32 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

48 Drugs in Development

48 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

379 FDF Dossiers, 64 FDA Orange Book, 222 Europe, 14 Canada, 48 Australia, 8 South Africa, 23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML, INJECTABLE;INJECTION - EQ 0.1MG BASE/ML, INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.5MG BASE/ML, INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 1 Gangwal Healthcare, 1 Pfanstiehl, 3 Kirsch Pharma, 2 Actylis, 1 BASF, 1 Finar, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 10 Direct Compression, 10 Taste Masking, 10 Parenteral, 7 Disintegrants & Superdisintegrants, 3 Granulation, 3 Co-Processed Excipients, 1 API Stability Enhancers, 1 Thickeners and Stabilizers, 1 Solubilizers, 1 Topical

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 43 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions, 47 Regulatory FDF Prices, 11 Annual Reports

MARKET PLACE

20 APIs, 16 FDF Dossiers

PATENTS & EXCLUSIVITIES

29 US Patents, 4 US Exclusivities, 7 Health Canada Patents

REF. STANDARDS & IMPURITIES

6 Others

6 Others

$ Xls

Filters

SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML

INJECTABLE;INJECTION - EQ 0.1MG BASE/ML

INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 0.5MG BASE/ML

INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Octreotide Acetate

Octreotide Acetate

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

60 API Suppliers

27 USDMF

9 CEP/COS

4 JDMF

8 EU WC

1 KDMF

20 NDC API

32 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

48 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

379 FDF Dossiers

64 FDA Orange Book

222 Europe

14 Canada

48 Australia

8 South Africa

23 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML

INJECTABLE;INJECTION - EQ 0.1MG BASE/ML

INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 0.5MG BASE/ML

INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;SUBCUTANEOUS - EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

14 SPI Pharma

1 Gangwal Healthcare

1 Pfanstiehl

3 Kirsch Pharma

2 Actylis

1 BASF

1 Finar

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

1 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

12 Chewable & Orodispersible Aids

10 Direct Compression

10 Taste Masking

10 Parenteral

7 Disintegrants & Superdisintegrants

3 Granulation

3 Co-Processed Excipients

1 API Stability Enhancers

1 Thickeners and Stabilizers

1 Solubilizers

1 Topical

DIGITAL CONTENT

2 Data Compilation #PharmaFlow

43 News #PharmaBuzz

GLOBAL SALES INFORMATION

12 US Medicaid Prescriptions

47 Regulatory FDF Prices

11 Annual Reports

MARKET PLACE

20 APIs

16 FDF Dossiers

PATENTS & EXCLUSIVITIES

29 US Patents

4 US Exclusivities

7 Health Canada Patents

REF. STANDARDS & IMPURITIES

INJECTABLE;INJECTION - EQ 0.2MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 1MG BASE/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons